You searched for viral vector - Page 2 of 20

Startup Scout 8 Sep 2022

Stratosvir is overcoming the viral immunotherapy delivery bottleneck

The U.K. startup Stratosvir is working to tackle the barriers to developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. Cancer immunotherapies have made great strides in the last decade, with some of the most important advances including CAR-T cell therapy and checkpoint inhibitors. One oncology field […]

September 8, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 16 Feb 2022

Startup Bags €50M Series A to Smash Gene Therapy Vector Limits

After closing Spain’s largest biopharma Series A round, the company SpliceBio has set its foundations in the gene therapy field and joins the push to deliver bigger therapeutic genes into patients. SpliceBio was founded in 2012 to tinker with a type of protein called inteins, which can stick peptides together to form new proteins. The […]

February 16, 2022 - 5 minutesmins - By Jonathan Smith

How to Develop a Robust Viral Safety Strategy for Gene Therapies

Gene therapies offer a promising hope of cure against rare diseases and other diseases like cancer, with over 1,000 ongoing clinical trials. The increasing need for safe and effective gene therapies is emphasizing the importance of viral safety within the viral vector manufacturing process. This will enable meeting global regulatory timelines and providing faster access […]

October 6, 2021 - 8 minutesmins - By Sudha Sundaram

News and Trends 4 Oct 2021

Non-Viral Gene Therapies Get €51M Boost, Though Challenges Remain

Although most gene therapy still relies on non-infectious viral vectors for delivery, a recent venture financing round for the Swiss company Anjarium Biosciences has shone the spotlight on alternative vectors, including lipid nanoparticles and electric pulses. Last month, Anjarium Biosciences raised €51M (CHF55.5M) in a Series A financing round to advance its gene delivery system […]

October 4, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 25 Mar 2021

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

The rise of adenoviral Covid-19 vaccines highlights the potential of companies using similar technology in other fields like cancer or gene therapy. However, complex challenges remain, such as circumventing immunity to adenoviral treatments. Earlier this month, Johnson & Johnson’s candidate became the first single-shot Covid-19 vaccine to get the EMA green light. The vaccine is […]

March 25, 2021 - 6 minutesmins - By Victor Kotsev

News and Trends 16 Apr 2020

Irish Biotech Raises €18M to Develop Non-Viral Cell Therapy Technology

The Irish company Avectas has closed a Series C round to develop cell therapies that don’t need viral vectors — a common bottleneck in cell therapy manufacturing. The fundraise of approximately €18M brings Avectas’ total equity funding to around €37M. The round was led by the company’s current shareholders, which include the serial life sciences […]

April 16, 2020 - 2 minutesmins - By Jonathan Smith

Eyevensis Eye Gene Therapy Approval France

News and Trends 11 Apr 2017

France Approves Trials for the First Eye Gene Therapy Free of Viral DNA

Eyevensys has received regulatory approval in France to start clinical trials using eye gene therapy technology that eliminates the need for viral vectors. The French biotech Eyevensys has been cleared by the French Product Security Regulatory Agency (ANSM) to proceed into the clinic with its EyeCET platform. The company is developing this gene therapy platform […]

April 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Jul 2016

Former uniQure and Evotec CEO pushes new viral candidate into Clinical Trials

Hookipa is starting its first clinical trial for a vaccine against human cytomegalovirus. This is the leading candidate of its platform for novel viral vectors, which promises to yield better vaccines for infections and cancer. Based in Vienna, Hookipa was founded in 2011 and is developing a new class of immunotherapies. Its strategy for novel […]

July 21, 2016 - 2 minutesmins - By Denise Neves Gameiro